About FDA

Office of Generic Drugs

About the Office of Generic Drugs

The Office of Generic Drugs (OGD) carefully reviews generic drug applications (known as abbreviated new drug applications or ANDAs) to ensure patients receive safe, effective and high-quality generic drugs. The additional funds, staff, and authorities provided by the Generic Drug User Fee Amendments of 2012 (GDUFA) have been essential in aiding OGD’s ability to speed the review process.

We are committed to upholding the public’s confidence in a program that continues to meet the ever-changing needs of public health.

Our Mission: OGD makes high quality, affordable medicines available to the public.
OGD’s responsibilities include:

  • Leading review of abbreviated new drug applications (ANDAs) and ensuring generic drugs are safe and effective
  • Serving as the main point of contact between abbreviated new drug application (ANDA) applicants and the FDA Generic Drug Program
  • Providing guidance and regulatory oversight to industry on a wide variety of clinical, scientific, and regulatory matters relating to generic drugs
  • Leading FDA’s fulfillment of GDUFA ANDA review commitments
  • Conducting and administering research in support of the GDUFA Regulatory Science Plan 

Contact FDA

301-595-1147 Fax
Office of Generic Drugs

Immediate Office

10903 New Hampshire Avenue

Silver Spring, MD 20993

Page Last Updated: 02/27/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English